HighLife SAS, a medtech company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced today it had closed a € 32 …
HighLife SAS, a medtech company focused on the development of a unique trans- catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment …
HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of …
This financing allows for the acceleration of the company’s clinical and R&D program HighLife SAS, an early-stage medtech company focused on the development of a unique trans-catheter mitral valve replacement …
First 3 activated clinical centers in France enroll patients HighLife SAS announced today the start of its European clinical study with the enrollment of the first 3 patients at major …
HighLife SAS announced today the successful treatment of 5 consecutive patients in its early feasibility clinical phase. The first three cases were carried out in Kiev (Ukraine) in the adult …
